|Founded 📆||Jersey (November 13, 2002)|
|Headquarters 🏙️||Saint Helier, Jersey (registered office)|
Area served 🗺️
|Roger New (CSO)|
|Products 📟||2 in clinical development and 3 in pre-clinical development|
Number of employees
Currently, the company doesn't have a marketed product, though its pipeline includes one drug that has recently completed phase II clinical development, one in phase II clinical development, and three in pre-clinical development.
|Capsulin OAD||Phase II clinical trial completed||Oral insulin for diabetes mellitus type 2|
|Capsulin IR||Phase II clinical trial||Oral insulin for diabetes mellitus type 1|
|Combulin||Pre-clinical development||Oral combination of insulin and insulin sensitizing agents for diabetes mellitus type 2|
|Oral GLP-1||Pre-clinical development||Improves glycaemic and diet control in diabetes mellitus type 2|
|Oral C-Petdide||Pre-clinical development||Reduces diabetic complications|
- "Entity Detail". www.jerseyfsc.org. Retrieved 1 August 2018.
- "'Insulin pill' hope for diabetes". 22 June 2007. Retrieved 1 August 2018 – via news.bbc.co.uk.
- Taylor, Phil (17 February 2016). "Oral biologics delivery still elusive". Retrieved 4 February 2018.
- "Diabetology Ltd - Clinical pipeline". Archived from the original on 14 August 2016. Retrieved 1 August 2018. Unknown parameter
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help EverybodyWiki by expanding it.|
|This article about the Bailiwick of Jersey is a stub. You can help EverybodyWiki by expanding it.|
This article "Diabetology Ltd" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Diabetology Ltd. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.